<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335508">
  <stage>Registered</stage>
  <submitdate>19/05/2010</submitdate>
  <approvaldate>30/11/2010</approvaldate>
  <actrnumber>ACTRN12610001046099</actrnumber>
  <trial_identification>
    <studytitle>Immune response to two-dose fractional inactivated poliovirus vaccine administered at 4- and 8- month of age</studytitle>
    <scientifictitle>Immune response and seroconversion in two-dose fractional inactivated poliovirus vaccine administered at 4 and 8 months of age</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>RPC329</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two fractional 0.1 ml IPV doses administered intradermally at 4 and 8 month old infants</interventions>
    <comparator>Full 0.5 ml IPV doses administered intramuscularly at 4- and 8-month of age</comparator>
    <control>Dose comparison</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Seroconversion by neutralization assay following 2 doses of IPV administered</outcome>
      <timepoint>9 months (using serum samples collected 4, 8 and 9 months of age)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>seroconversion after the first dose; and priming following a first dose; and seroconversion following a second dose</outcome>
      <timepoint>8 months (using serum samples collected at 4 and 8 months); at 8 months and 7 days (using serum samples collected at 8 and 8 months + 7 days); and 9 months (using serum samples collected at 8 and 9 months)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The primary endpoint for the study addendum is decrease in excretion prevalence following received of trivalent oral poliovirus vaccine (tOPV) in the National Immunization Days (NIDs) in February and April 2010</outcome>
      <timepoint>Stool samples will be collected after the February and March OPV mass administration during NIDs</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in saliva secretary Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) in oral fluid samples collected after a dose of tOPV</outcome>
      <timepoint>First at 9 months, and then before and after mass campaign administration of OPV</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in saliva secretory IgA following administration of OPV in mass campaigns</outcome>
      <timepoint>First at 9 months, then before and after mass campaign administration of OPV</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy infants (greater than 3rd percentile for height and weight) at enrollment living within the catchment area of
the participating polyclinics.</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>5</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Infants less than 3 percentile for height and weight, residence outside the catchment area, or families expecting
to move away during the study period, will be excluded. A diagnosis, suspicion or treatment of
immunodeficiency disorder (either in the participant or in a member of the immediate family) will render
the newborn ineligible for the study. Infants of mother age below legal age (&amp;lt;18 years) or with mentally
incapacity will not be eligible to participate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Mothers or caretakers will be invited to participate when they present for the 2-month routine immunization visit. Infants are enrolled following the 2-month clinical assessment visit. Study envelopes will be used to determine which study vaccines a study participant will receive.</concealment>
    <sequence>The use of random number generator (for randomization) will be used allocate study participants to a study arm, and its use will attempt to minimize/avoid bias.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Randomized, controlled trial of fractional (1/5 of a full dose) IPV given intradermally (intervention group) versus full-dose IPV given intramuscularly at age 4 and 8 months</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>320</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Cuba</country>
      <state>camaguey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>World Health Organization</primarysponsorname>
    <primarysponsoraddress>Avenue Appia 20
Geneva
CH-1211</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>Avenue Appia 20
Geneva
CH-1211</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Instituto Pedro Kouri (IPK)</othercollaboratorname>
      <othercollaboratoraddress>Autopista Novia del Mediodia km 61/2 entre Autopista Nacional y Carretera Central. La Lisa, Ciudad Habana, Cuba.</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Ministry of Health</othercollaboratorname>
      <othercollaboratoraddress>National Device Registration Authority: CECEM: Calle 4 No. 455 altos entre 19 y 21. Vedado, Ciudad Habana, Cuba</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Provincial Health Authority</othercollaboratorname>
      <othercollaboratoraddress>General Gomez # 5 entre Avellaneda y Republica. Camaguey, Cuba</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Regulatory Authority (CECMED)</othercollaboratorname>
      <othercollaboratoraddress>National Regulatory Authority: CECMED: Calle 200 # 1706 entre 17 y 19. Reparto Siboney, Playa, Ciudad Habana, Cuba.</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>World Health Organization</othercollaboratorname>
      <othercollaboratoraddress>Avenue Appia 20 

Geneva CH-1211</othercollaboratoraddress>
      <othercollaboratorcountry>Switzerland</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test the efficacy of a two dose schedule using either fractional or full dose IPV with the ultimate purpose to find a way for developing countries to adopt more affordable IPV use strategies in the future. It is hypothesized the fractional dose arm will be non-inferior to the full dose arm.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IPK Ethics Committee</ethicname>
      <ethicaddress>P.O. Box: 601 Marianao 13
Habana</ethicaddress>
      <ethicapprovaldate>13/03/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Cuba</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>WHO Research Ethics Review Committee</ethicname>
      <ethicaddress>World Health Organization
20, Avenue Appia,
Geneva 1211</ethicaddress>
      <ethicapprovaldate>18/05/2009</ethicapprovaldate>
      <hrec>RPC329</hrec>
      <ethicsubmitdate>6/05/2009</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Roland Sutter</name>
      <address>Avenue Appia 20
Geneva
CH-1211</address>
      <phone>+41 22 79 14682</phone>
      <fax />
      <email>sutterr@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Roland Sutter</name>
      <address>World Health Organization
Avenue Appia 20
Geneva</address>
      <phone>+41 22 79 14682</phone>
      <fax />
      <email>sutterr@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Roland Sutter</name>
      <address>Avenue Appia 20
Geneva
CH-1211</address>
      <phone />
      <fax />
      <email>sutterr@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>